{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:38:13Z","timestamp":1792715893012,"version":"4.5.0"},"reference-count":64,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: CardioOncology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jaccao.2026.09.003","type":"journal-article","created":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T19:30:36Z","timestamp":1792524636000},"page":"483-502","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Management and Surveillance of Immune Checkpoint Inhibitor Myocarditis: Managing the Aftermath"],"prefix":"10.1016","volume":"8","author":[{"given":"Tyler T.","family":"Morad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5728-7848","authenticated-orcid":false,"given":"Mohammad","family":"Keykhaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devon A.","family":"Terraciano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratyaksh K.","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4889-7454","authenticated-orcid":false,"given":"Eric H.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley F.","family":"Stein-Merlob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaccao.2026.09.003_bib1","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jaccao.2026.09.003_bib2","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1093\/eurheartj\/ehaf682","article-title":"Incidence and risk factors of immune checkpoint inhibitor myocardial and muscle toxicity: a French nationwide study","volume":"47","author":"Salem","year":"2026","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jaccao.2026.09.003_bib3","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1016\/j.jacc.2019.07.079","article-title":"Cardiovascular toxicities of immune checkpoint inhibitors: JACC review topic of the week","volume":"74","author":"Ball","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2026.09.003_bib4","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaccao.2026.09.003_bib5","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.jacc.2025.10.018","article-title":"Diagnosis and management of cardiovascular adverse effects of targeted oncology therapies: Bruton\u2019s tyrosine kinase, immune checkpoint, and vascular endothelial growth factor inhibitors: 2025 ACC concise clinical guidance","volume":"87","author":"Ganatra","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2026.09.003_bib6","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1001\/jamaoncol.2025.4543","article-title":"Immune checkpoint inhibitor-associated cardiovascular toxic effects: international cardio-oncology society position statement","volume":"12","author":"Herrmann","year":"2026","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jaccao.2026.09.003_bib8","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for immunotherapy of cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jaccao.2026.09.003_bib9","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaccao.2026.09.003_bib10","doi-asserted-by":"crossref","first-page":"4876","DOI":"10.4049\/jimmunol.1200389","article-title":"PD-1 protects against inflammation and myocyte damage in T cell-mediated myocarditis","volume":"188","author":"Tarrio","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.jaccao.2026.09.003_bib11","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/s41586-022-05432-3","article-title":"T cells specific for \u03b1-myosin drive immunotherapy-related myocarditis","volume":"611","author":"Axelrod","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.jaccao.2026.09.003_bib12","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1161\/CIRCULATIONAHA.121.056730","article-title":"Identification of pathogenic immune cell subsets associated with checkpoint inhibitor\u2013induced myocarditis","volume":"146","author":"Zhu","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2026.09.003_bib13","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1161\/CIRCULATIONAHA.122.062551","article-title":"Expansion of pathogenic cardiac macrophages in immune checkpoint inhibitor myocarditis","volume":"149","author":"Ma","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2026.09.003_bib14","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1161\/CIRCRESAHA.124.325652","article-title":"Novel therapeutic approach targeting CXCR3 to treat immunotherapy myocarditis","volume":"136","author":"Huang","year":"2025","journal-title":"Circ Res"},{"key":"10.1016\/j.jaccao.2026.09.003_bib15","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1158\/2159-8290.CD-22-1180","article-title":"Abatacept\/Ruxolitinib and screening for concomitant respiratory muscle failure to mitigate fatality of immune-checkpoint inhibitor myocarditis","volume":"13","author":"Salem","year":"2023","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jaccao.2026.09.003_bib16","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1006\/bbrc.1994.1947","article-title":"Interaction of tacrolimus(FK506) and its metabolites with FKBP and calcineurin","volume":"202","author":"Tamura","year":"1994","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jaccao.2026.09.003_bib17","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1567-5769(02)00210-2","article-title":"Mycophenolic acid inhibits inosine 5'-monophosphate dehydrogenase and suppresses immunoglobulin and cytokine production of B cells","volume":"3","author":"Jonsson","year":"2003","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.jaccao.2026.09.003_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.650295","article-title":"Ruxolitinib, a JAK1\/2 inhibitor, ameliorates cytokine storm in experimental models of hyperinflammation syndrome","volume":"12","author":"Huarte","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jaccao.2026.09.003_bib19","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.annonc.2020.05.005","article-title":"Tocilizumab for refractory severe immune checkpoint inhibitor-associated myocarditis","volume":"31","author":"Doms","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaccao.2026.09.003_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1646231","article-title":"Clinical features and HLA typing of immune checkpoint inhibitor-associated myasthenia gravis, myocarditis and myositis","volume":"15","author":"Lin","year":"2025","journal-title":"Front Oncol"},{"key":"10.1016\/j.jaccao.2026.09.003_bib21","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jaccao.2025.02.005","article-title":"Immune checkpoint inhibitor\u2013related myocarditis with or without concomitant myopathy: clinical findings and cardiovascular outcomes","volume":"7","author":"Itzhaki Ben Zadok","year":"2025","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.jaccao.2026.09.003_bib22","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.3390\/cancers17132063","article-title":"Management of triple M syndrome: a narrative review of immune checkpoint inhibitor-induced myasthenia gravis, myositis and myocarditis","volume":"17","author":"Furlepa","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jaccao.2026.09.003_bib23","article-title":"Features of myositis and myasthenia gravis in patients treated with immune checkpoint inhibitors: a multicentric, retrospective cohort study","volume":"50","author":"Plomp","year":"2025","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.jaccao.2026.09.003_bib24","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1161\/CIRCULATIONAHA.123.062405","article-title":"Cardiomuscular biomarkers in the diagnosis and prognostication of immune checkpoint inhibitor myocarditis","volume":"148","author":"Lehmann","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2026.09.003_bib25","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jacc.2019.11.049","article-title":"Global longitudinal strain and cardiac events in patients with immune checkpoint inhibitor-related myocarditis","volume":"75","author":"Awadalla","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2026.09.003_bib26","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.jaccao.2025.06.009","article-title":"Cardiac troponin screening and clinical outcomes in patients receiving immunotherapy","volume":"7","author":"Cheng","year":"2025","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.jaccao.2026.09.003_bib27","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1093\/eurheartj\/ehaf315","article-title":"Immune checkpoint inhibitor-associated myocarditis: a novel risk score","volume":"47","author":"Power","year":"2026","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jaccao.2026.09.003_bib28","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jacc.2024.10.080","article-title":"2024 ACC expert consensus decision pathway on strategies and criteria for the diagnosis and management of myocarditis","volume":"85","author":"Drazner","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2026.09.003_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.jocmr.2026.102743","article-title":"Prospective serial cardiovascular magnetic resonance imaging of immune checkpoint inhibitor myocarditis correlates with cardiovascular outcomes","volume":"28","author":"Kwan","year":"2026","journal-title":"J Cardiovasc Magn Reson"},{"key":"10.1016\/j.jaccao.2026.09.003_bib30","doi-asserted-by":"crossref","first-page":"e558","DOI":"10.1161\/CIR.0000000000001107","article-title":"An overview of telehealth in the management of cardiovascular disease: a scientific statement from the American Heart Association","volume":"146","author":"Takahashi","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2026.09.003_bib31","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1210\/clinem\/dgae250","article-title":"European society of endocrinology and endocrine society joint clinical guideline: diagnosis and therapy of glucocorticoid-induced adrenal insufficiency","volume":"109","author":"Beuschlein","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jaccao.2026.09.003_bib32","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1001\/jamaoncol.2024.3065","article-title":"Immune checkpoint inhibitor\u2013induced cardiotoxicity: a systematic review and meta-analysis","volume":"10","author":"Nielsen","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jaccao.2026.09.003_bib33","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2147\/OARRR.S4536","article-title":"Efficacy, safety, and tolerability of abatacept in the management of rheumatoid arthritis","volume":"1","author":"Lutt","year":"2009","journal-title":"Open Access Rheumatol"},{"key":"10.1016\/j.jaccao.2026.09.003_bib34","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s40262-023-01225-7","article-title":"Pharmacokinetics and pharmacodynamics of ruxolitinib: a review","volume":"62","author":"Appeldoorn","year":"2023","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jaccao.2026.09.003_bib35","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.revmed.2024.10.452","article-title":"JAK inhibitors (JAKi): mechanisms of action and perspectives in systemic and autoimmune diseases","volume":"46","author":"Chikhoune","year":"2025","journal-title":"La Revue de M\u00e9decine Interne"},{"key":"10.1016\/j.jaccao.2026.09.003_bib36","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1186\/s12967-024-05617-6","article-title":"Tofacitinib for the treatment of immune-related adverse events in cancer immunotherapy: a multi-center observational study","volume":"22","author":"Liu","year":"2024","journal-title":"J Transl Med"},{"key":"10.1016\/j.jaccao.2026.09.003_bib37","doi-asserted-by":"crossref","first-page":"5641","DOI":"10.1093\/rheumatology\/keaf356","article-title":"The therapeutic potential for JAK inhibitors for immune-related adverse events from checkpoint inhibitors: a review of the literature","volume":"64","author":"Nagra","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaccao.2026.09.003_bib38","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaccao.2026.09.003_bib39","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s004670050020","article-title":"Pharmacokinetics and tolerance of mycophenolate mofetil in renal transplant children","volume":"14","author":"Jacqz-Aigrain","year":"2000","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.jaccao.2026.09.003_bib40","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jaccao.2019.07.004","article-title":"Immune-checkpoint inhibitor-induced fulminant myocarditis and cardiogenic shock","volume":"1","author":"Itzhaki Ben Zadok","year":"2019","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.jaccao.2026.09.003_bib42","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/j.1399-0012.2008.00892.x","article-title":"Impact of gastrointestinal-related side effects on mycophenolate mofetil dosing and potential therapeutic strategies","volume":"22","author":"Bunnapradist","year":"2008","journal-title":"Clin Transpl"},{"key":"10.1016\/j.jaccao.2026.09.003_bib43","doi-asserted-by":"crossref","DOI":"10.3389\/frtra.2023.1160752","article-title":"Tacrolimus-why pharmacokinetics matter in the clinic","volume":"2","author":"Henkel","year":"2023","journal-title":"Front Transpl"},{"key":"10.1016\/j.jaccao.2026.09.003_bib44","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/art.38910","article-title":"Review: intravenous immunoglobulin and B cells: when the product regulates the producer","volume":"67","author":"S\u00e9\u00eft\u00e9","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jaccao.2026.09.003_bib45","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S1470-2045(17)30239-5","article-title":"Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN solid tumor): a phase 1a, multicohort, dose-escalation trial","volume":"18","author":"Heery","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jaccao.2026.09.003_bib46","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1002\/clc.24149","article-title":"Plasma exchange plus glucocorticoids in the treatment of immune checkpoint inhibitor-induced myocarditis: a case series and review","volume":"46","author":"Ke","year":"2023","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.jaccao.2026.09.003_bib47","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/imm.12178","article-title":"Impact of alemtuzumab treatment on the survival and function of human regulatory T cells in vitro","volume":"141","author":"Havari","year":"2014","journal-title":"Immunology"},{"key":"10.1016\/j.jaccao.2026.09.003_bib48","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1001\/jama.2023.3371","article-title":"Diagnosis and treatment of acute myocarditis: a review","volume":"329","author":"Ammirati","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.jaccao.2026.09.003_bib49","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1161\/CIR.0000000000000745","article-title":"Recognition and initial management of fulminant myocarditis","volume":"141","author":"Kociol","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2026.09.003_bib50","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0004709","article-title":"Targeting of natural killer cells by rabbit antithymocyte globulin and campath-1H: similar effects independent of specificity","volume":"4","author":"Stauch","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.jaccao.2026.09.003_bib51","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-006814","article-title":"Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events","volume":"11","author":"Fa'ak","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jaccao.2026.09.003_bib52","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1634\/theoncologist.2018-0028","article-title":"FDA approval summary: Tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome","volume":"23","author":"Le","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.jaccao.2026.09.003_bib53","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1161\/01.CIR.0000077913.60364.D2","volume":"107","author":"Chung","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2026.09.003_bib54","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20251717","article-title":"Immune checkpoint inhibitor-induced myocarditis is dependent on CD8 T cell-derived TNF and TNFR2 signaling","volume":"223","author":"Warrick","year":"2026","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaccao.2026.09.003_bib55","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1161\/CIRCULATIONAHA.125.076976","article-title":"CXCR6(+) T cells drive immune checkpoint inhibitor myocarditis","volume":"153","author":"Munir","year":"2026","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2026.09.003_bib56","doi-asserted-by":"crossref","first-page":"6640","DOI":"10.1038\/s41467-024-50996-5","article-title":"Gasdermin-E-mediated pyroptosis drives immune checkpoint inhibitor-associated myocarditis via cGAS-STING activation","volume":"15","author":"Sun","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.jaccao.2026.09.003_bib58","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.acvd.2024.12.005","article-title":"Abatacept dose-finding phase II trial for immune checkpoint inhibitors myocarditis (ACHLYS) trial design","volume":"118","author":"Salem","year":"2025","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.jaccao.2026.09.003_bib60","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMc1901677","article-title":"Abatacept for severe immune checkpoint inhibitor\u2013associated myocarditis","volume":"380","author":"Salem","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaccao.2026.09.003_bib61","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004699","article-title":"Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept","volume":"10","author":"Nguyen","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jaccao.2026.09.003_bib62","article-title":"Steroid-refractory immune checkpoint inhibitor\u2013induced myocarditis responsive to mycophenolate and antithymocyte globulin","volume":"30","author":"Wilson","year":"2025","journal-title":"JACC Case Rep"},{"key":"10.1016\/j.jaccao.2026.09.003_bib63","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.2169\/internalmedicine.4162-24","article-title":"Effectiveness of additional immunosuppressive drugs for corticosteroid-refractory immune checkpoint inhibitor-induced myocarditis: two case reports","volume":"64","author":"Sakaguchi","year":"2025","journal-title":"Intern Med"},{"key":"10.1016\/j.jaccao.2026.09.003_bib64","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1056\/NEJMc1903064","article-title":"Alemtuzumab for immune-related myocarditis due to PD-1 therapy","volume":"380","author":"Esfahani","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaccao.2026.09.003_bib65","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1038\/bjc.2017.253","article-title":"Successful use of equine anti-thymocyte globulin (ATGAM) for fulminant myocarditis secondary to nivolumab therapy","volume":"117","author":"Tay","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jaccao.2026.09.003_bib66","doi-asserted-by":"crossref","first-page":"4301","DOI":"10.1002\/ehf2.13545","article-title":"Keeping immune checkpoint inhibitor myocarditis in check: advanced circulatory mechanical support as a bridge to recovery","volume":"8","author":"Stein-Merlob","year":"2021","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jaccao.2026.09.003_bib67","article-title":"Case series of steroid-resistant immune checkpoint inhibitor associated myocarditis: a comparative analysis of corticosteroid and tofacitinib treatment","volume":"12","author":"Wang","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jaccao.2026.09.003_bib68","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jacep.2019.05.001","article-title":"Case series of ventricular tachycardia and myocarditis from programmed cell-death Protein-1 inhibitor treated with infliximab","volume":"5","author":"Padegimas","year":"2019","journal-title":"JACC Clin Electrophysiol"}],"container-title":["JACC: CardioOncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666087326003029?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666087326003029?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T23:43:11Z","timestamp":1792712591000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666087326003029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":64,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2666087326003029"],"URL":"https:\/\/doi.org\/10.1016\/j.jaccao.2026.09.003","relation":{},"ISSN":["2666-0873"],"issn-type":[{"value":"2666-0873","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management and Surveillance of Immune Checkpoint Inhibitor Myocarditis: Managing the Aftermath","name":"articletitle","label":"Article Title"},{"value":"JACC: CardioOncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaccao.2026.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}